Influenza Virus Nucleoprotein antibody (Influenza A Virus)

Catalog No. ABIN7794945

The Mouse Monoclonal anti-Influenza Virus Nucleoprotein antibody is suitable to detect Influenza Virus Nucleoprotein in samples from Influenza A Virus.

Quick Overview for Influenza Virus Nucleoprotein antibody (Influenza A Virus) (ABIN7794945)

Target: Influenza Virus Nucleoprotein (IV NP)

Reactivity: Influenza A Virus

Host: Mouse

Clonality: Monoclonal

Conjugate: Un-conjugated

Application: Please inquire

Clone: 274

Product Details

Purpose: Anti-Influenza A, Nucleocapsid (Clone 274) Purified No Carrier Protein

Specificity: Anti-Influenza A, Nucleocapsid (Clone 274) specifically targets an epitope on the Influenza A Nucleocapsid Protein Antigen Distribution The nucleocapsid protein is expressed in the internal nucleocapsid of Influenza A Background There are four types of Influenza (flu) viruses type A, B, C, and D. Influenza A and B viruses are routinely spread in people and other mammals, while also known for seasonal flu epidemics each year. Influenza A is the genus Alphainfluenzavirus of the virus family Orthomyxoviridae. Influenza A is classified into two main protein subtypes, hemagglutinin (HA) and neuraminidase (NA), located on the surface of the virus. Breaking down the proteins further, there are 18 hemagglutinin subtypes and 11 different neuraminidase subtypes1. Influenza A can be even further classified into specific clades (also known as groups) and sub-clades (also known as sub-groups) based on similarity of their HA/NA gene sequences1. The Nucleocapsid protein or nucleoprotein (NP) of the influenza virus A negative-strand RNA?s primary function is to encapsulate the virus genome for the purpose of RNA transcription, replication and packaging2. Specifically, NP is the most abundant viral protein in infected cells2, therefore the NP can be and has been used for anti-influenza drug development3 The NP of influenza A and B viruses share up to 38 % of their amino acid sequence, indicating region functionality differences at the amino acid level4

Purification: Recombinant antibodies are manufactured in an animal free facility using only in vitro protein free cell culture techniques and are purified by a multi-step process including the use of protein A or G to assure extremely low levels of endotoxins, leachable protein A or aggregates.

Purity: >=90 % monomer by analytical SEC and SDS-Page

Isotype: IgG1

Application Details

Restrictions: For Research Use only

Handling

Concentration: 1 μg/mL

Buffer: This recombinant monoclonal antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added. Due to inherent biochemical properties of antibodies, certain products may be prone to precipitation over time. Precipitation may be removed by aseptic centrifugation and/or filtration.

Preservative: Without preservative

Storage: 4 °C,-80 °C

Storage Comment: This antibody may be stored sterile as received at 2-8°C for up to one month. For longer term storage, aseptically aliquot in working volumes without diluting and store at <= -70°C.Avoid Repeated Freeze Thaw Cycles.

Target Details

Target: Influenza Virus Nucleoprotein (IV NP)

Alternative Name: Influenza A Virus Nucleocapsid

Target Type: Influenza Protein

Background: Common flu NP, Influenza A virus NP, NP, Nucleocapsid protein, Nucleoprotein, Protein N, Seasonal Influenza A (H1N1) Nucleocapsid Protein,